{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:44:12Z","timestamp":1792154652930,"version":"4.4.0"},"reference-count":78,"publisher":"Harborside Press, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The value of neoadjuvant radiotherapy (RT) after 5-fluorouracil with leucovorin, oxaliplatin, and irinotecan, with or without dose modifications [(m)FOLFIRINOX], for patients with borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC) is uncertain. <jats:bold>Methods:<\/jats:bold> We conducted an international retrospective cohort study including consecutive patients with BR PDAC who received (m)FOLFIRINOX as initial treatment (2012\u20132019) from the Trans-Atlantic Pancreatic Surgery Consortium. Because the decision to administer RT is made after chemotherapy, patients with metastases or deterioration after (m)FOLFIRINOX or a performance score \u22652 were excluded. Patients who received RT after (m)FOLFIRINOX were matched 1:1 by nearest neighbor propensity scores with patients who did not receive RT. Propensity scores were calculated using sex, age (\u226470 vs &gt;70 years), WHO performance score (0 vs 1), tumor size (0\u201320 vs 21\u201340 vs &gt;40 mm), tumor location (head\/uncinate vs body\/tail), number of cycles (1\u20134 vs 5\u20138 vs &gt;8), and baseline CA 19-9 level (\u2264500 vs &gt;500 U\/mL). Primary outcome was overall survival (OS) from diagnosis. <jats:bold>Results:<\/jats:bold> Of 531 patients who received neoadjuvant (m)FOLFIRINOX for BR PDAC, 424 met inclusion criteria and 300 (70.8%) were propensity score\u2013matched. After matching, median OS was 26.2 months (95% CI, 24.0\u201338.4) with RT versus 32.8 months (95% CI, 25.3\u201342.0) without RT (<jats:italic>P<\/jats:italic>=.71). RT was associated with a lower resection rate (55.3% vs 72.7%; <jats:italic>P<\/jats:italic>=.002). In patients who underwent a resection, RT was associated with a comparable margin-negative resection rate (&gt;1 mm) (70.6% vs 64.8%; <jats:italic>P<\/jats:italic>=.51), more node-negative disease (57.3% vs 37.6%; <jats:italic>P<\/jats:italic>=.01), and more major pathologic response with &lt;5% tumor viability (24.7% vs 8.3%; <jats:italic>P<\/jats:italic>=.006). The OS associated with conventional and stereotactic body RT approaches was similar (median OS, 25.7 vs 26.0 months; <jats:italic>P<\/jats:italic>=.92). <jats:bold>Conclusions:<\/jats:bold> In patients with BR PDAC, neoadjuvant RT following (m)FOLFIRINOX was associated with more node-negative disease and better pathologic response in patients who underwent resection, yet no difference in OS was found. Routine use of RT cannot be recommended based on these data.<\/jats:p>","DOI":"10.6004\/jnccn.2022.7008","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T19:39:40Z","timestamp":1657741180000},"page":"783-791.e1","source":"Crossref","is-referenced-by-count":37,"title":["Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study"],"prefix":"10.6004","volume":"20","author":[{"given":"Quisette P.","family":"Janssen","sequence":"first","affiliation":[{"name":"1Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York;"},{"name":"2Department of Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob L.","family":"van Dam","sequence":"additional","affiliation":[{"name":"2Department of Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura R.","family":"Prakash","sequence":"additional","affiliation":[{"name":"3Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deesje","family":"Doppenberg","sequence":"additional","affiliation":[{"name":"4Department of Surgery, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Crane","sequence":"additional","affiliation":[{"name":"5Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper H.J.","family":"van Eijck","sequence":"additional","affiliation":[{"name":"2Department of Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susannah G.","family":"Ellsworth","sequence":"additional","affiliation":[{"name":"6Department of Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Jarnagin","sequence":"additional","affiliation":[{"name":"1Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Paniccia","sequence":"additional","affiliation":[{"name":"8Department of Surgery, Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha","family":"Reyngold","sequence":"additional","affiliation":[{"name":"5Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G.","family":"Besselink","sequence":"additional","affiliation":[{"name":"4Department of Surgery, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.G.","family":"Katz","sequence":"additional","affiliation":[{"name":"3Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Wei D.","family":"Tzeng","sequence":"additional","affiliation":[{"name":"3Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer H.","family":"Zureikat","sequence":"additional","affiliation":[{"name":"8Department of Surgery, Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Groot Koerkamp","sequence":"additional","affiliation":[{"name":"2Department of Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice C.","family":"Wei","sequence":"additional","affiliation":[{"name":"1Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"_","family":"_","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref401","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","article-title":"Challenges of guarantee-time bias","volume":"31","author":"Giobbie-Hurder","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fonc.2020.00041","article-title":"Neoadjuvant treatment in patients with resectable and borderline resectable pancreatic cancer","volume":"10","author":"Janssen","year":"2020","journal-title":"Front Oncol"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamasurg.2019.2277","article-title":"Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma","volume":"154","author":"Maggino","year":"2019","journal-title":"JAMA Surg"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ejso.2016.10.021","article-title":"Chemotherapy and radiation components of neoadjuvant treatment of pancreatic head adenocarcinoma: impact on perioperative mortality and long-term survival","volume":"43","author":"Franko","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1002\/cncr.30856","article-title":"Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review","volume":"123","author":"de Geus","year":"2017","journal-title":"Cancer"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"ref501","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4016","article-title":"Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: long-term results of the multicenter randomized phase III PREOPANC trial [abstract]","volume":"39","author":"Van Eijck","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djz073","article-title":"Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"111","author":"Janssen","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1245\/s10434-018-6931-6","article-title":"How does chemoradiotherapy following induction FOLFIRINOX improve the results in resected borderline or locally advanced pancreatic adenocarcinoma? An AGEO-FRENCH multicentric cohort","volume":"26","author":"Pietrasz","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2020.01.007","article-title":"Neoadjuvant treatment strategies for resectable pancreas cancer: a propensity-matched analysis of the National Cancer Database","volume":"143","author":"Xiang","year":"2020","journal-title":"Radiother Oncol"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djz073","article-title":"Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"111","author":"Janssen","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.suc.2013.02.008","article-title":"Resection margins in pancreatic cancer","volume":"93","author":"Verbeke","year":"2013","journal-title":"Surg Clin North Am"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1002\/cncr.30856","article-title":"Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review","volume":"123","author":"de Geus","year":"2017","journal-title":"Cancer"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.hpb.2021.04.027","article-title":"The effect of preoperative chemotherapy and chemoradiotherapy on pancreatic fistula and other surgical complications after pancreatic resection: a systematic review and meta-analysis of comparative studies","volume":"23","author":"van Dongen","year":"2021","journal-title":"HPB (Oxford)"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1177\/00031348211038581","article-title":"Neoadjuvant radiotherapy is associated with improved pathologic outcomes and survival in resected stage II-III pancreatic adenocarcinoma treated with multiagent neoadjuvant chemotherapy in the modern era","volume":"87","author":"Hue","year":"2021","journal-title":"Am Surg"},{"key":"ref91","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4016","article-title":"Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: long-term results of the multicenter randomized phase III PREOPANC trial [abstract]","volume":"39","author":"Van Eijck","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1186\/s12885-017-3441-z","article-title":"Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas","volume":"17","author":"Katz","year":"2017","journal-title":"BMC Cancer"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"ref641","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.377","article-title":"Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas [abstract]","volume":"39","author":"Katz","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1245\/s10434-021-10276-8","article-title":"The added value of radiotherapy following neoadjuvant FOLFIRINOX for resectable and borderline resectable pancreatic cancer: a systematic review and meta-analysis","volume":"28","author":"Janssen","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.amjsurg.2016.11.039","article-title":"Neoadjuvant external beam radiation is associated with no benefit in overall survival for early stage pancreatic cancer","volume":"213","author":"Lutfi","year":"2017","journal-title":"Am J Surg"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.hpb.2020.01.013","article-title":"Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes","volume":"22","author":"Cloyd","year":"2020","journal-title":"HPB (Oxford)"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41416-021-01341-w","article-title":"Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort","volume":"124","author":"Auclin","year":"2021","journal-title":"Br J Cancer"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fonc.2020.00041","article-title":"Neoadjuvant treatment in patients with resectable and borderline resectable pancreatic cancer","volume":"10","author":"Janssen","year":"2020","journal-title":"Front Oncol"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.suc.2013.02.008","article-title":"Resection margins in pancreatic cancer","volume":"93","author":"Verbeke","year":"2013","journal-title":"Surg Clin North Am"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamasurg.2019.2277","article-title":"Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma","volume":"154","author":"Maggino","year":"2019","journal-title":"JAMA Surg"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1245\/s10434-018-07131-8","article-title":"Clinical impact of neoadjuvant chemotherapy and chemoradiotherapy in borderline resectable pancreatic cancer: analysis of 884 patients at facilities specializing in pancreatic surgery","volume":"26","author":"Nagakawa","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.32756","article-title":"Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): an international systematic review and meta-analysis","volume":"126","author":"Tchelebi","year":"2020","journal-title":"Cancer"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1245\/s10434-018-07131-8","article-title":"Clinical impact of neoadjuvant chemotherapy and chemoradiotherapy in borderline resectable pancreatic cancer: analysis of 884 patients at facilities specializing in pancreatic surgery","volume":"26","author":"Nagakawa","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"ref751","volume-title":"TNM Classification of Malignant Tumours","author":"Sobin","year":"2009"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1002\/cncr.30706","article-title":"Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation","volume":"123","author":"Zhong","year":"2017","journal-title":"Cancer"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.amjsurg.2016.11.039","article-title":"Neoadjuvant external beam radiation is associated with no benefit in overall survival for early stage pancreatic cancer","volume":"213","author":"Lutfi","year":"2017","journal-title":"Am J Surg"},{"key":"ref171","volume-title":"AJCC Cancer Staging Manual","author":"Kakar","year":"2016"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MPA.0000000000001231","article-title":"Chemotherapy versus chemoradiation as preoperative therapy for resectable pancreatic ductal adenocarcinoma: a propensity score adjusted analysis","volume":"48","author":"Cloyd","year":"2019","journal-title":"Pancreas"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1245\/s10434-021-10276-8","article-title":"The added value of radiotherapy following neoadjuvant FOLFIRINOX for resectable and borderline resectable pancreatic cancer: a systematic review and meta-analysis","volume":"28","author":"Janssen","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.hpb.2020.01.013","article-title":"Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes","volume":"22","author":"Cloyd","year":"2020","journal-title":"HPB (Oxford)"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jamcollsurg.2007.12.020","article-title":"Borderline resectable pancreatic cancer: the importance of this emerging stage of disease","volume":"206","author":"Katz","year":"2008","journal-title":"J Am Coll Surg"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.ejso.2020.02.037","article-title":"Borderline or locally advanced pancreatic adenocarcinoma: a single center experience on the FOLFIRINOX induction regimen","volume":"46","author":"Garnier","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1177\/00031348211038581","article-title":"Neoadjuvant radiotherapy is associated with improved pathologic outcomes and survival in resected stage II-III pancreatic adenocarcinoma treated with multiagent neoadjuvant chemotherapy in the modern era","volume":"87","author":"Hue","year":"2021","journal-title":"Am Surg"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"djw323","DOI":"10.1093\/jnci\/djw323","article-title":"Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies","volume":"109","author":"Yao","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.21037\/jgo-20-391","article-title":"Pathology reporting of margin status in locally advanced pancreatic cancer: challenges and uncertainties","volume":"12","author":"Soer","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"ref361","article-title":"Surgical complications in a multicenter randomized trial comparing preoperative chemoradiotherapy and immediate surgery in patients with resectable and borderline resectable pancreatic cancer (PREOPANC trial) [published online November 12, 2020]","author":"van Dongen","journal-title":"Ann Surg"},{"key":"ref341","volume-title":"TNM Classification of Malignant Tumours","author":"Sobin","year":"2009"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.ejso.2020.02.037","article-title":"Borderline or locally advanced pancreatic adenocarcinoma: a single center experience on the FOLFIRINOX induction regimen","volume":"46","author":"Garnier","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2020.01.007","article-title":"Neoadjuvant treatment strategies for resectable pancreas cancer: a propensity-matched analysis of the National Cancer Database","volume":"143","author":"Xiang","year":"2020","journal-title":"Radiother Oncol"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13014-019-1254-8","article-title":"Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1)","volume":"14","author":"Gao","year":"2019","journal-title":"Radiat Oncol"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MPA.0000000000001231","article-title":"Chemotherapy versus chemoradiation as preoperative therapy for resectable pancreatic ductal adenocarcinoma: a propensity score adjusted analysis","volume":"48","author":"Cloyd","year":"2019","journal-title":"Pancreas"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1186\/s12885-017-3441-z","article-title":"Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas","volume":"17","author":"Katz","year":"2017","journal-title":"BMC Cancer"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41416-021-01341-w","article-title":"Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort","volume":"124","author":"Auclin","year":"2021","journal-title":"Br J Cancer"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.32756","article-title":"Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): an international systematic review and meta-analysis","volume":"126","author":"Tchelebi","year":"2020","journal-title":"Cancer"},{"key":"ref771","article-title":"Surgical complications in a multicenter randomized trial comparing preoperative chemoradiotherapy and immediate surgery in patients with resectable and borderline resectable pancreatic cancer (PREOPANC trial) [published online November 12, 2020]","author":"van Dongen","journal-title":"Ann Surg"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","article-title":"Challenges of guarantee-time bias","volume":"31","author":"Giobbie-Hurder","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"djw323","DOI":"10.1093\/jnci\/djw323","article-title":"Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies","volume":"109","author":"Yao","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1002\/cncr.30706","article-title":"Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation","volume":"123","author":"Zhong","year":"2017","journal-title":"Cancer"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"ref201","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1977"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13014-019-1254-8","article-title":"Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1)","volume":"14","author":"Gao","year":"2019","journal-title":"Radiat Oncol"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.hpb.2021.04.027","article-title":"The effect of preoperative chemotherapy and chemoradiotherapy on pancreatic fistula and other surgical complications after pancreatic resection: a systematic review and meta-analysis of comparative studies","volume":"23","author":"van Dongen","year":"2021","journal-title":"HPB (Oxford)"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ejso.2016.10.021","article-title":"Chemotherapy and radiation components of neoadjuvant treatment of pancreatic head adenocarcinoma: impact on perioperative mortality and long-term survival","volume":"43","author":"Franko","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1245\/s10434-018-6931-6","article-title":"How does chemoradiotherapy following induction FOLFIRINOX improve the results in resected borderline or locally advanced pancreatic adenocarcinoma? An AGEO-FRENCH multicentric cohort","volume":"26","author":"Pietrasz","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"ref581","volume-title":"AJCC Cancer Staging Manual","author":"Kakar","year":"2016"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.21037\/jgo-20-391","article-title":"Pathology reporting of margin status in locally advanced pancreatic cancer: challenges and uncertainties","volume":"12","author":"Soer","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0000000000000738","article-title":"Validation of a proposed tumor regression grading scheme for pancreatic ductal adenocarcinoma after neoadjuvant therapy as a prognostic indicator for survival","volume":"40","author":"Lee","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"ref611","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1977"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0000000000000738","article-title":"Validation of a proposed tumor regression grading scheme for pancreatic ductal adenocarcinoma after neoadjuvant therapy as a prognostic indicator for survival","volume":"40","author":"Lee","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"ref231","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.377","article-title":"Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas [abstract]","volume":"39","author":"Katz","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jamcollsurg.2007.12.020","article-title":"Borderline resectable pancreatic cancer: the importance of this emerging stage of disease","volume":"206","author":"Katz","year":"2008","journal-title":"J Am Coll Surg"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/7\/article-p783.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/20\/7\/article-p783.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T18:15:14Z","timestamp":1657908914000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/7\/article-p783.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":78,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2022.7008","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}